Physician profile
Christina M Froiland
NPI 1487874913
$22,427.50
in general payments reported to CMS, 2019-2025
28 companies · $3,965 in 2025
The $3,965 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $806 · 2022: $1,128 · 2023: $3,086 · 2024: $13K · 2025: $3,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,751 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,800 · Consulting Fee: $4,048 · Travel and Lodging: $3,393 · Education: $502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,750.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,800.00 |
| Consulting Fee | $4,048.00 |
| Travel and Lodging | $3,392.72 |
| Education | $502.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,601.84 | 2021-2025 | |
| Leo Pharma INC. | $2,183.22 | 2021-2025 | Adbry, Anzupgo |
| Ucb, INC. | $1,453.18 | 2023-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $1,343.10 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $946.52 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $776.73 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $739.20 | 2022-2025 | |
| Genzyme Corporation | $619.28 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $564.73 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $530.38 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $351.53 | 2021-2023 | Ilumya |
| Dermavant Sciences, INC. | $207.85 | 2023-2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $179.99 | 2025 | |
| Incyte Corporation | $145.16 | 2025 | Opzelura |
| Pfizer INC. | $141.16 | 2022-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $116.41 | 2021-2025 | Wegovy |
| Janssen Scientific Affairs, LLC | $102.92 | 2022-2024 | Tremfya |
| Axogen | $82.98 | 2021 | |
| Genentech USA, INC. | $79.52 | 2024 | Xolair |
| Amgen INC. | $63.77 | 2021-2022 | |
| Glaxosmithkline, LLC. | $49.47 | 2022 | |
| Exact Sciences Corporation | $42.44 | 2024 | Cologuard Collection Kit |
| Galderma Laboratories, L.P. | $32.80 | 2025 | Nemluvio |
| Teva Pharmaceuticals USA, INC. | $19.09 | 2023 | Airduo Digihaler |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.56 | 2024 | Caplyta |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.66 | 2022 | |
| Acadia Pharmaceuticals INC | $15.54 | 2024 | Daybue |
| Organon LLC | $4.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Froiland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.